Description
GHRH analog approved for HIV-associated lipodystrophy
Tesamorelin promotes the body’s natural GH release with clinically recognized effects on reducing visceral fat and improving lipid metabolism.
- Falutz J, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291-4304. PMID: 20554713 | DOI: 10.1210/jc.2010-0490
- Fourman LT, et al. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight. 2020;5(16):e140134. PMID: 32701508 | DOI: 10.1172/jci.insight.140134
- Russo SC, et al. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS. 2024;38(12):1758-1764. PMID: 38905488 | DOI: 10.1097/QAD.0000000000003965
